[CELG] Celgene Corporation


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 78.56 B

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 118.93 Change: 1.06 (0.9%)
Ext. hours: Change: 0 (0%)

chart CELG

Refresh chart

Strongest Trends Summary For CELG

CELG is in the medium-term up 9% above S&P in 2 months. In the long-term up 2251% in 26 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies to treat cancer and immune-inflammatory related diseases in the United States and internationally. The company?s commercial stage products include REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma, myelodysplastic syndromes (MDS), and mantle cell lymphoma; VIDAZA, a pyrimidine nucleoside analog to treat intermediate-2 and high-risk MDS, and chronic myelomonocytic leukemia, as well as acute myeloid leukemia (AML); ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancers; and POMALYST/IMNOVID for the treatment of multiple myeloma. Its commercial stage products also comprise THALOMID for the patients with multiple myeloma and for the acute treatment of the cutaneous manifestations of erythema nodosum leprosum; ISTODAX to treat cutaneous T-cell lymphoma; and FOCALIN, FOCALIN XR, and RITALIN LA products. The company?s

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding774.6 M EPS3.09 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters 14.91% Sales Growth - Q/Q9.47% P/E39.6
P/E To EPS Growth P/S9.32 P/BV12.43 Price/Cash Per Share10.49
Price/Free Cash Flow29.58 ROA12.38% ROE34.76% ROI15.22%
Current Ratio3.34 Quick Ratio3.2 Long Term Debt/Equity0.9 Debt Ratio0.47
Gross Margin95.19% Operating Margin31.72% Net Profit Margin26.08% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities-951.3 M Cash From Investing Activities239.7 M Cash From Operating Activities1.14 B Gross Profit2.18 B
Net Profit356.2 M Operating Profit412.4 M Total Assets17.75 B Total Current Assets9.88 B
Total Current Liabilities2.96 B Total Debt7.62 B Total Liabilities11.42 B Total Revenue2.28 B
Technical Data
High 52 week98.91 Low 52 week59.21 Last close95.14 Last change-0.16%
RSI77.77 Average true range1.31 Beta1.07 Volume2.51 M
Simple moving average 20 days3.15% Simple moving average 50 days1.44% Simple moving average 200 days10.08%
Performance Data
Performance Week1.35% Performance Month2.95% Performance Quart-0.39% Performance Half8.22%
Performance Year4.27% Performance Year-to-date48.45% Volatility daily0.86% Volatility weekly1.92%
Volatility monthly3.93% Volatility yearly13.63% Relative Volume218.43% Average Volume4.36 M
New High New Low


2019-09-18 10:33:02 | Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More

2019-09-18 10:33:02 | Acceleron Discontinues Mid-Stage Muscular Dystrophy Study

2019-09-17 17:50:09 | Celgene CELG Gains But Lags Market: What You Should Know

2019-09-17 10:39:02 | Karyopharm Signs $150M Royalty Agreement to Support Xpovio

2019-09-17 10:14:02 | The Zacks Analyst Blog Highlights: Celgene, Sinopec, HSBC, Vertex Pharmaceuticals and Prudential Financial

2019-09-16 14:25:06 | Top Stock Reports for Celgene, Sinopec & HSBC

2019-09-16 08:48:12 | Amgen's Kyprolis Combo Improves PFS in Multiple Myeloma Study

2019-09-13 10:30:02 | Celgene's CELG Leukemia Candidate Meets Endpoints in Study

2019-09-13 09:18:00 | Bristol-Myers Stock Is Looking Good After Otezla Deal, Analyst Says

2019-09-13 08:00:53 | Amgen Stock Is The Biggest Biotech Stock, But Should You Buy It?

2019-09-13 07:40:02 | The Daily Biotech Pulse: All Eyes On Aimmune, Ritter Stumbles In Late-Stage Study, Catalyst Shelves Offering Plans

2019-09-12 16:30:00 | Celgene Announces Phase 3 QUAZAR® AML-001 Study of CC-486 as Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia Met Primary and Key Secondary Endpoints

2019-09-12 09:41:01 | J&J's Ponesimod Superior to Aubagio in Relapsing MS Patients

2019-09-11 17:50:09 | Celgene CELG Outpaces Stock Market Gains: What You Should Know

2019-09-10 18:00:10 | FDA Grants Orphan Drug Status to Acceleron's PAH Candidate

2019-09-09 07:30:00 | Data from Ozanimod Clinical Development Program in Relapsing Forms of Multiple Sclerosis to Be Presented at the 35th Congress of the European Committee for Treatment and Research in Multiple Sclerosis

2019-09-08 09:00:00 | Better Buy: Amgen vs. Celgene

2019-09-07 12:30:00 | Is Bristol-Myers Squibb a Buy?

2019-09-06 15:06:00 | Why Amgen's Spending Billions to Buy This 1 Drug; Plus Heart Disease Has a New Enemy

2019-09-06 08:39:12 | Roche's Tecentriq Combo Gets EU Nod for Difficult Lung Cancer

2019-09-06 05:21:06 | China biotech group shares slide over accusation of sales inflation

2019-09-05 17:50:09 | Celgene CELG Gains But Lags Market: What You Should Know

2019-09-05 16:51:07 | 3 Special Situations Gurus Are Buying

2019-09-04 09:39:01 | Roche Extends Offer to Acquire Spark Therapeutics Yet Again

2019-09-03 17:46:09 | Top-Performing Biotech ETFs YTD

2019-09-03 07:02:11 | 5 Cancer-Fighting Stocks to Add to Your Portfolio

2019-09-03 06:30:00 | The 3 Best Health Care Stocks So Far This Year

2019-08-30 17:45:09 | Celgene CELG Stock Sinks As Market Gains: What You Should Know

2019-08-29 11:24:03 | Roche's Tecentriq Combo Gets EU Nod for Critical Breast Cancer

2019-08-29 10:18:02 | Geron GERN Stock Rises 40% in 2019 So Far: Here's Why

2019-08-29 09:31:01 | Why Is Celgene CELG Up 6.1% Since Last Earnings Report?

2019-08-28 18:55:10 | What Investors Need to Know About the Celgene, Amgen & Bristol-Myers Deals

2019-08-28 13:56:00 | Bristol-Myers Squibb Gains Europe's Approval for Empliciti

2019-08-28 10:54:19 | Celgene Strikes Cancer Immunotherapy Deal With Immatics For Up To $1.59B

2019-08-28 10:38:02 | The Zacks Analyst Blog Highlights: Bristol-Myers Squibb Company, Celgene, Exact Sciences, Pfizer and Guardant Health

2019-08-28 10:34:02 | Biotech Stock Roundup: AMGN to Buy CELG's Otezla, ALXN's Soliris Gets EC Nod & More

2019-08-28 10:15:02 | Bristol-Myers' Empliciti Gets EMA Nod for Label Expansion

2019-08-28 06:28:10 | Alexion Wins EC Nod for Soliris in Nervous System Disorder

2019-08-27 11:01:27 | 4 Biotech Stocks to Buy That Are on the Move

2019-08-27 10:55:02 | Amgen to Buy Celgene's Otezla for $13.4B: Is it a Good Buy?

2019-08-27 10:18:00 | Amgen Paid Too Much for Otezla. Why One Analyst Says It Was the Right Thing to Do.

2019-08-27 10:07:02 | Company News for Aug 27, 2019

2019-08-27 10:05:02 | Amgen to Buy Celgene's Otezla: 5 ETF Drugs

2019-08-27 09:24:01 | 3 Cancer Treatment Stocks to Enrich Your Portfolio

2019-08-27 08:58:12 | Alexion ALXN Down 3.2% After Amgen Buys Otezla From Celgene

2019-08-27 08:05:12 | Bristol-Myers Announces Sale of Celgene's Otezla to Amgen

2019-08-27 00:00:27 | Amgen adds Otezla to its medicine cabinet

2019-08-26 22:04:55 | US Stock Market Overview – Stock Surge as Trump Flip Flops Lifting Dow Industrials

2019-08-26 18:12:03 | Amgen and Celgene’s Otezla Deal: Key Highlights

2019-08-26 16:58:38 | What Happened in the Stock Market Today